Table 4.

Available meta-analyses assessing temporary ovarian suppression with GnRHa during chemotherapy in patients with malignancies other than breast cancer or not restricted to only breast cancer trials.

Authors	Year	Disease	No. of Included Studies (no. of RCTs)	No. of Patients	Overall Results
Clowse et. al. [93]	2009	Autoimmune diseases, HL and NHL	9 (2)	366	Protection for POI
Ben-Aharon et al. [94]	2010	Autoimmune diseases, breast cancer, HL and NHL	16 (5)	681	Protection for POI (not in RCTs)
Kim et al. [95]	2010	Autoimmune diseases, breast cancer, HL and NHL	11 (3)	654	Protection for POI
Bedaiwy et al. [96]	2011	Breast cancer, ovarian cancer and HL	6 (6)	340	Protection for POI (not for pregnancy)
Zhang et al. [97]	2013	HL and NHL	7 (3)	434	Protection for POI (not for pregnancy)
Sun et al. [98]	2014	Breast cancer, ovarian cancer and HL	8 (8)	621	Protection for POI (not for pregnancy)
Del Mastro et al. [99]	2014	Breast cancer, ovarian cancer, HL and NHL	9 (9)	765	Protection for POI
Elgindy et al. [59]	2015	Breast cancer, ovarian cancer, HL and NHL	10 (10)	907	No protection
Senra et al. [100]	2018	Breast cancer, HL and NHL	13 (13)	1208	Protection for POI (also for pregnancy)
Hickman et al. [101]	2018	Breast cancer, ovarian cancer, HL and NHL	10 (10)	1051	Protection for POI
Sofiyeva et al. [102]	2019	Autoimmune diseases, breast cancer, HL and NHL	18 (11)	1043	Protection for POI
Zheng et al. [103]	2019	Breast cancer, HL and NHL	12 (12)	1413	Protection for POI (not for pregnancy)
Chen et al. [104]	2019	Breast cancer, ovarian cancer and HL	12 (12)	1369	Protection for POI (not for pregnancy)
Luong et al. [105]	2020	Autoimmune diseases	3 (1)	93	Protection for POI

Abbreviations: POI, premature ovarian insufficiency; GnRHa, gonadotropin-releasing hormone agonist; HL, Hodgkin lymphoma; NHL, non-Hodgkin lymphoma.